RFP Financial Group LLC Acquires 322 Shares of Novo Nordisk A/S (NYSE:NVO)

RFP Financial Group LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 73.2% in the first quarter, according to its most recent filing with the SEC. The firm owned 762 shares of the company’s stock after acquiring an additional 322 shares during the period. RFP Financial Group LLC’s holdings in Novo Nordisk A/S were worth $98,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Cravens & Co Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 1.0% in the 1st quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock valued at $1,059,000 after purchasing an additional 85 shares during the period. Sage Rhino Capital LLC boosted its holdings in Novo Nordisk A/S by 0.7% during the first quarter. Sage Rhino Capital LLC now owns 12,320 shares of the company’s stock worth $1,582,000 after buying an additional 89 shares during the last quarter. U.S. Capital Wealth Advisors LLC grew its position in shares of Novo Nordisk A/S by 0.6% during the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock worth $1,595,000 after buying an additional 90 shares during the period. Essex LLC increased its stake in shares of Novo Nordisk A/S by 2.0% in the 1st quarter. Essex LLC now owns 4,684 shares of the company’s stock valued at $601,000 after acquiring an additional 90 shares during the last quarter. Finally, JCIC Asset Management Inc. raised its position in shares of Novo Nordisk A/S by 0.3% in the 1st quarter. JCIC Asset Management Inc. now owns 27,552 shares of the company’s stock valued at $3,538,000 after acquiring an additional 90 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on NVO. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, July 1st. Argus increased their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $163.00 price objective on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Stock Up 1.2 %

NYSE NVO traded up $1.60 during trading on Friday, hitting $131.59. The stock had a trading volume of 4,315,458 shares, compared to its average volume of 4,459,800. Novo Nordisk A/S has a 12 month low of $77.96 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The company’s 50-day moving average price is $138.93 and its two-hundred day moving average price is $127.37. The company has a market capitalization of $590.51 billion, a PE ratio of 45.38, a P/E/G ratio of 1.35 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.4 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.